The Enterprise DG of the European Commission retained Charles River Associates to undertake a study investigating whether there is a worldwide crisis in innovation in the pharmaceutical sector, the reasons behind this crisis, and the tools available to kick-start innovation.
Assessing the implications of centralized drug price setting to investment in clinical development for HIV treatments
The Build Back Better Act, which is under consideration for passage into law includes price controls in Medicare Part B and D and price caps more broadly. In...